Clinical Characteristics of 11 Patients Treated with Convalescent Plasma in 2 Studies
Study and Patient No. . | Sex . | Age, y . | Time From Symptom Onset to Plasma Transfusion, d . | Respiratory Failure . | Convalescent Plasma Treatments, No. . | Convalescent Plasma Dosage, mL . | Survival . |
---|---|---|---|---|---|---|---|
Shen et al [6] | |||||||
1 | Male | 73 | 24 | Yes | 1 | 400 | Yes |
2 | Male | 60 | 14 | Yes | 1 | 400 | Yes |
3 | Female | 50 | 22 | Yes | 1 | 400 | Yes |
4 | Female | 36 | 21 | Yes | 1 | 400 | Yes |
5 | Male | 60 | 23 | Yes | 1 | 400 | Yes |
1 | Male | 32 | 13 | Yes | 1 | 200 | Yes |
Zeng et al [10] | |||||||
2 | Female | 30 | 26 | Yes | 2 | 600 | No |
3 | Male | 76 | 33 | Yes | 2 | 400 | No |
4 | Male | 61 | 30 | Yes | 2 | 600 | No |
5 | Male | 62 | 23 | Yes | 1 | 200 | No |
6 | Male | 83 | 30 | Yes | 1 | 200 | No |
Study and Patient No. . | Sex . | Age, y . | Time From Symptom Onset to Plasma Transfusion, d . | Respiratory Failure . | Convalescent Plasma Treatments, No. . | Convalescent Plasma Dosage, mL . | Survival . |
---|---|---|---|---|---|---|---|
Shen et al [6] | |||||||
1 | Male | 73 | 24 | Yes | 1 | 400 | Yes |
2 | Male | 60 | 14 | Yes | 1 | 400 | Yes |
3 | Female | 50 | 22 | Yes | 1 | 400 | Yes |
4 | Female | 36 | 21 | Yes | 1 | 400 | Yes |
5 | Male | 60 | 23 | Yes | 1 | 400 | Yes |
1 | Male | 32 | 13 | Yes | 1 | 200 | Yes |
Zeng et al [10] | |||||||
2 | Female | 30 | 26 | Yes | 2 | 600 | No |
3 | Male | 76 | 33 | Yes | 2 | 400 | No |
4 | Male | 61 | 30 | Yes | 2 | 600 | No |
5 | Male | 62 | 23 | Yes | 1 | 200 | No |
6 | Male | 83 | 30 | Yes | 1 | 200 | No |
Clinical Characteristics of 11 Patients Treated with Convalescent Plasma in 2 Studies
Study and Patient No. . | Sex . | Age, y . | Time From Symptom Onset to Plasma Transfusion, d . | Respiratory Failure . | Convalescent Plasma Treatments, No. . | Convalescent Plasma Dosage, mL . | Survival . |
---|---|---|---|---|---|---|---|
Shen et al [6] | |||||||
1 | Male | 73 | 24 | Yes | 1 | 400 | Yes |
2 | Male | 60 | 14 | Yes | 1 | 400 | Yes |
3 | Female | 50 | 22 | Yes | 1 | 400 | Yes |
4 | Female | 36 | 21 | Yes | 1 | 400 | Yes |
5 | Male | 60 | 23 | Yes | 1 | 400 | Yes |
1 | Male | 32 | 13 | Yes | 1 | 200 | Yes |
Zeng et al [10] | |||||||
2 | Female | 30 | 26 | Yes | 2 | 600 | No |
3 | Male | 76 | 33 | Yes | 2 | 400 | No |
4 | Male | 61 | 30 | Yes | 2 | 600 | No |
5 | Male | 62 | 23 | Yes | 1 | 200 | No |
6 | Male | 83 | 30 | Yes | 1 | 200 | No |
Study and Patient No. . | Sex . | Age, y . | Time From Symptom Onset to Plasma Transfusion, d . | Respiratory Failure . | Convalescent Plasma Treatments, No. . | Convalescent Plasma Dosage, mL . | Survival . |
---|---|---|---|---|---|---|---|
Shen et al [6] | |||||||
1 | Male | 73 | 24 | Yes | 1 | 400 | Yes |
2 | Male | 60 | 14 | Yes | 1 | 400 | Yes |
3 | Female | 50 | 22 | Yes | 1 | 400 | Yes |
4 | Female | 36 | 21 | Yes | 1 | 400 | Yes |
5 | Male | 60 | 23 | Yes | 1 | 400 | Yes |
1 | Male | 32 | 13 | Yes | 1 | 200 | Yes |
Zeng et al [10] | |||||||
2 | Female | 30 | 26 | Yes | 2 | 600 | No |
3 | Male | 76 | 33 | Yes | 2 | 400 | No |
4 | Male | 61 | 30 | Yes | 2 | 600 | No |
5 | Male | 62 | 23 | Yes | 1 | 200 | No |
6 | Male | 83 | 30 | Yes | 1 | 200 | No |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.